Entries by Michael Kuhrt

EFPIA: Engaging for pharma innovation

In April, Nathalie Moll has taken on her new job as Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Moll is also Secretary General of Europe’s largest biotech industry group EuropaBio. 

Endomag: Going beyond the horizons

Cancer healthcare company Endomag, founded in 2007 as a spin-out from the University College London (UCL) and the University of Houston, has appointed Peter Keen as non-executive director. Keen will focus on supporting the company as it further extends its international reach.

Early Certainty Initiative: Disincentive to patenting

The decision of the European Patent Office to examine all patent applications within 12 months can unintentionally block companies from filing for life sciences patents in Europe, says Gavin Recchia, Principal of one of Australia’s largest patent attorneys’ firms.

Dentons: All about taxes

?? Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of ?? Dentons since 2014.

Asit biotech: Expertise in vaccines

Belgian clinical-stage immunotherapy developer  Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011. 

A clear path ahead for the bioeconomy

There’s no way around it: renewables are the future, Matti Heikkilä believes. European Biotechnology talked to the CTO of Finnish bioeconomy company MetGen about what bio-based products need to bring to the table to usurp their fossil-based counterparts. 

Europe’s shield against falsified medicines

The pharmaceutical industry of the European Union is currently toiling at a veritably Herculean task. They jointly took up the fight against falsified pharmaceuticals in the legal supply chain. Forgers have discovered that falsified drugs are a lucrative business. However, the EU legislature has recognised this risk, and responded by passing the Falsified Medicines Directive in 2011. In 2016, it was put in more concrete terms with the delegated regulation, which stipulates the implementation of the directive for prescription drugs.